Yaxin Liu1, Tao Tian1, Huijun Zhang2, Linggen Gao3, Xianliang Zhou4. 1. Department of Cardiology, FuWai Hospital and Cardiovascular Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Beijing 100037, China. 2. Department of Geriatric Cardiology, General Hospital of Beijing Armed Police Corps Beijing 100027, China. 3. Department of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China. Electronic address: gaolinggen@163.com. 4. Department of Cardiology, FuWai Hospital and Cardiovascular Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Beijing 100037, China. Electronic address: fuwailab15@gmail.com.
Abstract
OBJECTIVE: High level of homocysteine induces injury of endothelial cells and predicts adverse cardiovascular events. The objective was to assess the effect of homocysteine-lowering therapy with folic acid on flow-mediated vasodilation in patients with coronary artery disease. METHODS AND RESULTS: We conducted a meta-analysis of randomized controlled trials identified from PubMed, Embase, the Cochrane Library. Eight studies were included. Homocysteine-lowering therapy with folic acid in patients with coronary artery disease significantly improve FMD as compared with placebo using random-effect model (SMD = 1.65 with 95% CI 1.12-2.17, p < 0.001). Subgroup analysis of subjects revealed that lipid-lowering therapy, study duration, and Delphi criteria had no effects on FMD. CONCLUSION: Our meta-analysis demonstrated that folic acid supplementation can significantly improve endothelial dysfunction as assessed by FMD in the brachial artery in patients with coronary heart disease.
OBJECTIVE: High level of homocysteine induces injury of endothelial cells and predicts adverse cardiovascular events. The objective was to assess the effect of homocysteine-lowering therapy with folic acid on flow-mediated vasodilation in patients with coronary artery disease. METHODS AND RESULTS: We conducted a meta-analysis of randomized controlled trials identified from PubMed, Embase, the Cochrane Library. Eight studies were included. Homocysteine-lowering therapy with folic acid in patients with coronary artery disease significantly improve FMD as compared with placebo using random-effect model (SMD = 1.65 with 95% CI 1.12-2.17, p < 0.001). Subgroup analysis of subjects revealed that lipid-lowering therapy, study duration, and Delphi criteria had no effects on FMD. CONCLUSION: Our meta-analysis demonstrated that folic acid supplementation can significantly improve endothelial dysfunction as assessed by FMD in the brachial artery in patients with coronary heart disease.
Authors: Walter F Tetzlaff; Tomás Meroño; Martin Menafra; Maximiliano Martin; Eliana Botta; Maria D Matoso; Patricia Sorroche; Juan A De Paula; Laura E Boero; Fernando Brites Journal: World J Cardiol Date: 2017-05-26